Multidisciplinary Treatment of Primary Melanoma

Katharine Yao, Glen Balch, David J. Winchester

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


This article covers the multidisciplinary treatment of primary melanoma. Excision margins and the need for sentinel lymphadenectomy are mainly dictated by the Breslow thickness although exceptions to this dictum do exist. Interferon is the only FDA approved adjuvant therapy for high risk melanoma although its overall survival benefit is minimal. Trials examining different doses or duration of interferon therapy have not demonstrated any promising survival data so far. There have been several randomized vaccine trials for melanoma but none have shown an overall survival benefit. Research into T-cell regulation continues and will hopefully bring promise for the future of melanoma treatment.

Original languageEnglish (US)
Pages (from-to)267-281
Number of pages15
JournalSurgical Clinics of North America
Issue number1
StatePublished - Feb 2009


  • Breslow thickness
  • Immunotherapy
  • Interferon
  • Melanoma
  • Melanoma vaccine
  • Sentinel node
  • Thin melanomas

ASJC Scopus subject areas

  • Surgery


Dive into the research topics of 'Multidisciplinary Treatment of Primary Melanoma'. Together they form a unique fingerprint.

Cite this